News

Sharikas hired to attract Life Science companies to Greater Richmond

The Greater Richmond Partnership (“GRP”) has hired Kiryako Sharikas to join the team as Business Development Manager – Life Sciences. Sharikas will focus on targeting life science and pharmaceutical companies interested in expanding to the Richmond Region.

“Kiryako’s experience in marketing will translate well as he markets the region as the #1 mid-sized location in the U.S. for life science companies to invest,” said Jennifer Wakefield, President + CEO of the Greater Richmond Partnership. “With Kiryako on the team, GRP will now have a dedicated point of contact to expand the shared effort to make our region the capital of advanced pharmaceutical manufacturing.”

Sharikas has more than eight years of experience in digital marketing for employers including CoStar Group, Sheltering Arms, Compare.com and NetSearch. Sharikas’ experience will be a major asset as he transitions to the new role. Sharikas is a graduate of Virginia Commonwealth University and Reynolds Community College.

 

Read more here.

Recent News

06/11/2026

Adial Pharmaceuticals Announces Acquisition of Azora Therapeutics and up to $64 Million Financing

Adial Pharmaceuticals, Inc. (Nasdaq: ADIL) (“Adial” or the “Company”) today announced that it has acquired Azora Therapeutics, Inc. (“Azora”), a biopharmaceutical company developing treatments for serious inflammatory diseases. The acquisition brings Azora’s lead asset AT177, a proprietary colon‑targeted aryl hydrocarbon receptor (AhR) agonist designed to enable localized activation with limited systemic exposure, into Adial’s pipeline.

06/11/2026

Luna Labs Launches 3 Waves Venture Spinout to Commercialize Advanced Vestibular Stimulation Technology

Luna Labs today announced the launch of 3 Waves, Inc. (“3Waves”), a dual-use spinout company that was established to commercialize advanced virtual and mixed reality technologies for defense, commercial simulation, and medical applications. As part of the spinout, 3Waves and Mayo Clinic executed an exclusive license to support the development of next-generation vestibular stimulation systems

06/02/2026

TearSolutions Receives FDA Orphan Drug and Fast Track Designations for Lacripep® in Neurotrophic Keratitis and Initiates Phase 2 Clinical Trial with First Patients Dosed

TearSolutions, Inc. (“TearSolutions”), a clinical-stage biotechnology company developing novel ophthalmic therapeutics, today announced receiving Food and Drug Administration (FDA) Orphan Drug (ODD) and Fast Track Designations for Lacripep in Neurotrophic Keratitis (NK) and initiating a Phase 2 clinical trial with first patients dosed. The FDA’s ODD provides incentives, including tax credits for clinical testing and